Targets of immunotherapy of chronic viral infections and cancer
The symposium will be hosted by Rīga Stradiņš University, May 24-26. Registered participants are welcome at Dzirciema iela 16. Here is the full program for the event:
| Start | Finish | Title | Presenter |
|---|---|---|---|
| For questions or suggestions, please contact the organizers. | |||
| 8:30 | 9:10 | Registration | |
| 9:10 | 9:20 | Welcome and opening | Uldis Berkis, the Director of the Research Department of Riga Stradins University |
| 9:20 | 10:00 | What is the most efficient immunotherapy to Epstein-Barr virus (EBV) infection? | Ingemar Ernberg (Karolinska Institutet, Stockholm, Sweden) |
| 10:00 | 10:40 | HBV - viral vaccine and the first vaccine against cancer | Irina Sominskaya (Biomedical Research and Study Center, Riga, Latvia) |
| 10:40 | 11:00 | COFFEE BREAK | |
| 11:00 | 11:30 | INaked DNA as a vehicle in immune prevention and immune therapy of viral infections | Maria Isaguliants (Riga Stradins University, Riga, Latvia, Gamaleya Research Center of Epidemiology and Microbiology, Moscow, Russia, and Karolinska Institutet, Stockholm, Sweden) |
| 11:30 | 11:45 | A novel efficient HBV vaccine candidate based on HBc and preS1 components presented by VLPs | Andris Dishlers (Biomedical Research and Study Center, Riga, Latvia) |
| 11:45 | 12:00 | Immunogenicity in mice of plasmid DNA encoding HCV core and alternative reading frame proteins | Juris Jansons (Biomedical Research and Study Center, Riga, Latvia) |
| 12:00 | 12:20 | REGISTRATION (continued) | |
| 12:20 | 13:20 | LUNCH | |
| 13:20 | 14:00 | Nanovaccine HIV: prophylactic and therapeutic DNAs | Britta Wahren (Karolinska Institutet, Stockholm, Sweden) |
| 14:00 | 14:40 | Targets for HCV prophylactic and therapeutic vaccines | Lars Frelin (Karolinska Institutet, Stockholm, Sweden) |
| 14:40 | 15:00 | Delivery of naked DNA for immunization and gene therapy: optimization using human explant model and reporter genes | Stefan Petkov (Karolinska Institutet, Stockholm, Sweden) |
| 10:40 | 11:00 | COFFEE BREAK | |
| 15:20 | 15:30 | Modified Klintrup-Makinen inflammation score in relation to invasive properties of colorectal cancer | Inese Drike (Riga Stradins University, Riga, Latvia) |
| 15:30 | 15:40 | Parafibromin: a reliable molecular marker in parathyroid neoplasms. | Lubov Kolomencikova (Riga Stradins University, Riga, Latvia) |
| 15:40 | 15:50 | p53 protein expression and its correlation with cell proliferation in colorectal cancer | Inese Drike (Riga Stradins University, Riga, Latvia) |
| 15:50 | 16:10 | p53 protein as a potential target of cancer vaccines in glioblastomas | Arvids Jakovlevs (Riga Stradins Universitet, Riga, Latvia) |
| 16:10 | 16:20 | Expression of aberrant p53 protein in gastric cancer | Mareks Marcuks (Riga Stradins Universitet, Riga, Latvia) |
| 16:20 | 16:40 | Poster presentations (5 min, 3-5 slides) | |
| 16:40 | 17:00 | Poster viewing | |
| 19:00 | 21:00 | DINNER | |
| 09:00 | 09:40 | Introductory lecture on cancer development and vaccine targets. Laminin isoforms in tumor invasion and metastasis | Manuel Patarroyo (Karolinska Institutet, Stockholm, Sweden) |
| 09:40 | 10:20 | Chromatin remodeling and cancer, the role of factors of chromatin remodeling in carcinogenesis | Anki Östlund (Stockholm University, Stockholm, Sweden) |
| 10:20 | 10:35 | Activation of transcription factors by carcinogenic Orai mutants | Rainer Schindl (JKU University of Linz, Austria) |
| 10:40 | 11:00 | COFFEE BREAK | |
| 11:00 | 11:30 | Oxidative stress and carcinogenesis | Alexander Ivanov (Engelhardt Institute of Molecular Biology, Moscow, Russia) |
| 11:30 | 12:10 | Metabolic reprogramming - a hallmark of oncogenic viruses | Birke Bartosch (INSERM, Lyon, France) |
| 12:10 | 12:25 | Understanding ciHHV-6 reactivation through miRNAs and mitochondrial network: a new prospective towards better therapy | Bhupesh Prusty (University of Würzburg, Würzburg, Germany) |
| 12:25 | 12:40 | S18 family of mitochondrial ribosomal proteins: evolutionary history and gly132 polymorphism in colon carcinoma | Muhammad Mushtaq |
| 13:00 | 14:00 | LUNCH | |
| 14:00 | 14:40 | Vaccines in cancer immunotherapy: experience of Ukrainian oncologists | Karaman Olga (Institute of Experimental Oncology and Radiology, Kiev, Ukraine) |
| 14:40 | 15:20 | Telomerase reverse transcriptase as a target of anticancer vaccines | Jon Amund Kyte (The Norwegian Radium Hospital, Oslo, Norway) |
| 15:20 | 15:40 | Immunotherapeutic targeting of carcinoembryonic antigen | Britta Wahren (Karolinska Institutet, Stockholm, Sweden) |
| 15:40 | 16:00 | COFFEE BREAK | |
| 16:00 | 16:40 | Mutant p53 vaccination prospects | Galina Selivanova (Karolinska Institutet , Stockholm, Sweden) |
| 16:40 | 17:20 | Mitochondrial protein S18-2: functions and possibility of vaccine targeting | Elena Kashuba (Institute of Experimental Oncology and Radiology, Kiev, Ukraine) |
| 17:20 | 17:30 | Impact of low penetrance variants on breast cancer morbidity and prognosis | Monta Ustinova (Riga Stradins University, Riga, Latvia) |
| 09:00 | 09:40 | Immunotherapy of melanoma | Dace Pjanova (Biomedical Research and Study Center, Riga, Latvia) |
| 09:40 | 10:00 | Cancer immunotherapy: oncolytic virotherapy in Latvia | Dace Reihmane (Riga Stradins University, Riga, Latvia) |
| 10:00 | 10:40 | NK mediated cytolysis in glioblastoma, triggered by viral therapy | Marion Schneider (University Hospital Ulm, Ulm, Germany) |
| 10:40 | 10:45 | Effect of Rigvir on viable cancer cell count in vitro | Telle V et. al |
| 10:45 | 11:10 | COFFEE BREAK | |
| 11:10 | 11:50 | Nanoparticles as the basis for treatment of HIV/AIDS and cancer | Elżbieta Pedziwiatr-Werbicka (University of Lodz, Lodz, Poland) |
| 11:50 | 12:30 | Immunotherapy for HPV-related disease in HIV-positive and HIV-negative men and women | Joel Palefsky (University of California, San Francisco, USA) |
| 12:30 | 13:10 | Breaking through low immunogenicity of HIV-1 reverse transcriptase in therapeutic vaccines against drug resistance in HIV infection. | Elizaveta Starodubova (Chumakov Institute of Poliomyelitis and Viral Encephalitides, Engelhard Institute of Molecular Biology, Moscow, Russia, and Karolinska Institutet, Stockholm, Sweden) |
| 13:10 | 14:10 | LUNCH | |
| 14:10 | 14:50 | DNA, RNA or viral particles: alphaviruses as vaccine vectors | Karl Ljungberg (Karolinska Institutet, Stockholm, Sweden) |
| 14:50 | 15:10 | Nucleotide-modified RNA-aptamers selected to the cell-surface of Burkitt lymphoma cells suppress Burkitt lymphoma but not T-cell lymphoma cell proliferation in vitro | Irina Kholodnjuka Irina (Riga Stradins University, Riga, Latvia) |
| 15:10 | 15:50 | Viral versus non-viral vectors for anticancer gene therapy | Dzmitry Shcharbin & Maria Bryszewska (Lodz University, Lodz, Poland) |
| 16:00 | 16:15 | Closing of the meeting | |
| 09:00 | 09:30 | Gene expression profiling, microarrays - state of the art and their applications in hematooncology | |
| 09:35 | 10:05 | Chronic Lymphocytic Leukemia (CLL) - then and now; Familial predisposition and genetic risk factors for lymphoma; Genomic and epigenomic heterogeneity in CLL; treatment of CLL - where are we heading? | |
| 10:10 | 10:40 | Apoptosis, signaling pathways - common denominator in paradigm of CLL; how to use a knowledge from signaling pathways to design therapy for individual patient, glycodendrimers and what impact might they have on leukemia. State-of-the-art and future perspective. The significance of the data obtained. | |
| 10:40 | 11:00 | COFFEE BREAK | |
| 11:00 | 11:30 | Colloidal stability and DVLO theory. The electrical double layer and zeta potential. Factors affecting zeta potential; Huckel and Smoluchowski's approximations used for the conversion of electrophoretic mobility into zeta potential; How good is zeta potential measurement in water treatment? | |
| 11:35 | 12:05 | Brownian motion and light scattering theories. What is the hydrodynamic diameter, z-average size, polydispersity index. The differences between intensity, volume and number distribution. | |
| 12:10 | 14:40 | Applications of zeta potential and size measurements for nanoparticles characterization | |
| 12:40 | 14:40 | LUNCH | |
| 13:40 | 14:25 | Physical principles. Photochemistry. Quantum yield. Lifetime. Jablonski diagram. | |
| 14:30 | 15:15 | Anisotropy. Quenching. Steady-state fluorescence and phosphorescence. Time-resolved fluorescence and phosphorescence. Fluorescent and phosphorescent probes. | |
| 15:20 | 16:00 | Applications of fluorescence and phosphorescence for gene delivery systems. | |